Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

This study is following patients who receive the NG SI IMT 3X — a miniature telescope implanted inside the eye — to treat advanced age-related macular degeneration (AMD). AMD destroys the central vision needed for reading and recognizing faces, and in its end stage leaves patients with only peripheral (side) vision. The implantable telescope magnifies central images onto a healthier area of the retina, effectively giving patients usable central vision again for many daily tasks. The study monitors how well the implant performs and how safe it is in real-world patients over the medium to long term. Participants will undergo vision testing, eye examinations, and training programs to learn how to use the device effectively. You may be eligible if... - You are 55 years or older - You have end-stage AMD (geographic atrophy or disciform scar) involving the central area of both eyes - You have cataracts in the eye to be operated on - Your best-corrected vision in both eyes is between 20/80 and 20/800 - You have adequate peripheral vision in the non-operated eye - You show at least a 5-letter improvement using a telescope simulator - You are willing and able to participate in the post-operative training program You may NOT be eligible if... - You have active choroidal neovascularization (wet AMD) or were treated for it in the last 6 months - You have a history of retinal detachment, retinal vascular disease, or optic nerve disease - You have diabetic retinopathy or retinitis pigmentosa - You have glaucoma or elevated eye pressure (>22 mmHg) - You have had previous surgery in the operative eye - You have a high degree of myopia (>6.0 D) or hyperopia (>4.0 D) Talk to your doctor to see if this trial is right for you.